4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Polycystic Kidney Disease by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 71 ongoing clinical trials involving Polycystic Kidney Disease
Of the 71 trials,30 trials are in Phase III
Furthermore, 26 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Polycystic Kidney Disease by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Polycystic Kidney Disease, a Genetic Disorders. The largest number of ongoing clinical trials for Polycystic Kidney Disease is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Polycystic Kidney Disease-related drug trials.

Otsuka Holdings Co Ltd: The leading ongoing Polycystic Kidney Disease related clinical trial sponsor

Otsuka Holdings Co Ltd is the top sponsor for Polycystic Kidney Disease-related ongoing clinical trials.

Reata Pharmaceuticals Inc, Toranomon Hospital, Palladio Biosciences Inc and Kadmon Corp LLC are among other notable clinical trial sponsors involved in Polycystic Kidney Disease. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Polycystic Kidney Disease

Tolvaptan (Samsca), Tolvaptan (Jinarc, Jynarque, Samsca) and Tolvaptan (Vaptan) are among the key marketed drugs involving Polycystic Kidney Disease.

Tolvaptan (Samsca) is a diuretic, belongs to vasopressin antagonists. It functions via Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) Antagonist mechanism of action. Tolvaptan is formulated as tablets and granules for oral route of administration. Tolvaptan was first approved in 2009 and is marketed globally in the US, UK, China, Japan, Germany, and France by Otsuka America Pharmaceutical Inc and its subsidiaries.

Tolvaptan (Jinarc, Jynarque, Samsca) is a diuretic. It functions via Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) Antagonist mechanism of action. Tolvaptan is formulated as tablets and granules for oral route of administration. Tolvaptan was first approved in 2015 and is marketed globally in the US, UK, France, Germany and Australia by Otsuka America Pharmaceutical Inc and its subsidiaries.